Music Therapy to Restore Motor Deficits After Stroke
NCT02208219, Not applicable, Unknown, University of Barcelona
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Music Therapy to Restore Motor Deficits After Stroke | ClinicalTrials.gov |
| NCT number | NCT02208219 | ClinicalTrials.gov |
| Status | Unknown | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 120 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | University of Barcelona | ClinicalTrials.gov |
| Conditions | Stroke, Paresis | ClinicalTrials.gov |
| Interventions | Music-supported Therapy, home-based Music-supported Therapy, Conventional treatment | ClinicalTrials.gov |
| First posted | 2014-08-05 | ClinicalTrials.gov |
| Last updated | 2016-10-28 | ClinicalTrials.gov |
Registered outcomes 26
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in the performance of movements with the paretic upper extremity assessed by the Action Research Arm Test (Carroll, 1965; Lyle, 1981). | Baseline, after intervention, 6 months after intervention | ClinicalTrials.gov | |
| Secondary | Motor function: Change in the functional use of the paretic upper extremity using the Arm Paresis Score Test (Wade et al., 1983) | Baseline, after intervention, 6 months after intervention | ClinicalTrials.gov | |
| Secondary | Motor function: Change in motor performance in the paretic upper extremity assessed by in the Box and Block Test (Mathiowetz et al., 1985) | Baseline, after intervention, 6 months after intervention | ClinicalTrials.gov | |
| Secondary | Motor function: Change in motor performance in the paretic upper extremity assessed by the Nine Hole Pegboard Test (Parker et al., 1986) | Baseline, after intervention, 6 months after intervention | ClinicalTrials.gov | |
| Secondary | Motor function: Change in the functional use of the paretic upper extremity assessed by the Chedoke McMaster Stroke Impairment Inventory (Gowland et al., 1993) | Baseline, after intervention, 6 months after intervention | ClinicalTrials.gov | |
| Secondary | Motor function: Change in the physical motor properties of the paretic upper extremity assessed by in the Fugl-Meyer Assessment (Fugl-Meyer et al., 1975) | Baseline, after intervention, 6 months after intervention | ClinicalTrials.gov | |
| Secondary | Motor function: Change in strength in the paretic upper extremity assessed with a grip dynamometer (E-Link, Biometrics Ltd); | Baseline, after intervention, 6 months after intervention | ClinicalTrials.gov | |
| Secondary | Motor function: Change in movements performed with the paretic upper extremity using Computerized movement analysis (CMS 50, Zebris, Isny, Germany). | Baseline, after intervention, 6 months after intervention | ClinicalTrials.gov | |
| Secondary | Cognitive function: Change in working memory using the Digit Span subtest from the Wechsler Adult Intelligence Scale III (Wechsler, 1997) | Baseline, after intervention, 6 months after intervention | ClinicalTrials.gov | |
| Secondary | Cognitive function: Change in verbal learning assessed with the Rey Auditory Verbal Learning Test (Rey, 1964); | Baseline, after intervention, 6 months after intervention | ClinicalTrials.gov | |
| Secondary | Cognitive function: Change in short-term memory using the Story Recall subtest from the Rivermead Behavioral Memory Test (Wilson et al., 1985) | Baseline, after intervention, 6 months after intervention | ClinicalTrials.gov | |
| Secondary | Cognitive function: Change in executive functions using the scores of the Stroop Task (Stroop, 1935) | Baseline, after intervention, 6 months after intervention | ClinicalTrials.gov | |
| Secondary | Cognitive function: Change in executive functions using the Trail Making Test (Reitan, 1958) | Baseline, after intervention, 6 months after intervention | ClinicalTrials.gov | |
| Secondary | Emotional and Quality of Life: Change in mood assessed with the Profile of Mood States (POMS; McNair et al., 1971) | Baseline, after intervention, 6 months after intervention | ClinicalTrials.gov | |
| Secondary | Emotional and Quality of Life: Change in depressive symptoms using the Beck Depression Inventory Scale (Beck et al., 1996) | Baseline, after intervention, 6 months after intervention | ClinicalTrials.gov | |
| Secondary | Emotional and Quality of Life: Change in positive and negative emotions assessed with the test Positive and Negative Affect Scale (PANAS, Watson et al., 1988) | Baseline, after intervention, 6 months after intervention | ClinicalTrials.gov | |
| Secondary | Emotional and Quality of Life: Change in apathy using the Apathy evaluation scale (Self scale; Marin, 1991) | Baseline, after intervention, 6 months after intervention | ClinicalTrials.gov | |
| Secondary | Emotional and Quality of Life: Change in quality of life using the Stroke Specific Quality of Life Scale (SS-QOL, Williams et al., 1999) | Baseline, after intervention, 6 months after intervention | ClinicalTrials.gov | |
| Secondary | Emotional and Quality of Life: Change in health perceived quality using the Health survey questionnaire SF36 (Alonso et al., 1995) | Baseline, after intervention, 6 months after intervention | ClinicalTrials.gov | |
| Secondary | Brain Imaging: Change in grey and white matter structures assessed with Magnetic Resonance Imaging | Baseline, after intervention, 6 months after intervention | * A standard T1-weighted 3D-MPRAGE image. \[TE = 4.82 ms, TR = 2500 ms, TI = 1100 ms, flip angle = 7°, matrix = 256×256×192, voxel size = 1.0x1.0x1.0 mm\]. * Diffusion-weighted (DW-MRI). \[TR = 13475ms, TE = 102 ms, matrix= 128 ×128; FOV=25.6 cm, voxel size= 2x2x2 mm\] (60 axial slices). Diffusion will be measured along 64 non-collinear directions, using a single b-value of 1500 s/mm2 and interleaved with 9 non-diffusion b=0 images. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 7
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Block Copy Test | Secondary outcome | ConductCognition |
| Digit Span Test | Secondary outcome | ConductCognition |
| Short Story Recall | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
| Verbal Learning | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)